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Uterine sarcoma is a very aggressive and highly lethal disease. Even after a comprehensive staging
surgery or en block cytoreduction surgery followed by multimodality therapy (often chemotherapy and/
or radiation therapy), many patients relapse or present with distant metastases, and ﬁnally die of dis-
eases. The worst outcome of uterine sarcomas is partly because of their rarity, unknown etiology, and
highly divergent genetic aberration. Uterine sarcomas are often classiﬁed into four distinct subtypes,
including uterine leiomyosarcoma, low-grade uterine endometrial stromal sarcoma, high-grade uterine
endometrial stromal sarcoma, and undifferentiated uterine sarcoma. Currently, evidence from tumor
biology found that these tumors showed alternation and/or mutation of genomes and the intracellular
signal pathway. In addition, some preclinical studies showed promising results for targeting receptor
tyrosine kinase signaling, phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway,
various kinds of growth factor pathways, Wnt/beta-catenin signaling pathway, transforming growth
factor b/bone morphogenetic protein signal pathway, aurora kinase A, MDM2 proto-oncogene, histone
deacetylases, sex hormone receptors, certain types of oncoproteins, and/or loss of tumor suppressor
genes. The current review is attempted to summarize the recurrent advance of targeted therapy for
uterine sarcomas.
Copyright © 2016, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
In previous issues of the Taiwanese Journal of Obstetrics and
Gynecology, we have reviewed the clinical characteristics of all main
subtypes of uterine sarcomas, including uterine leiomyosarcoma
(uLMS), low-grade uterine endometrial stromal sarcoma, high-
grade uterine endometrial stromal sarcoma, and uterineics and Gynecology, Taipei
ad, Taipei, 112, Taiwan.
w, phwang@ym.edu.tw,
rk.
necology Systematic Review
bstetrics & Gynecology. Published bundifferentiated sarcoma [1,2]. In addition, one of the variant-form
uterine carcinomas [uterine carcinosarcoma (UCS)], categorized as
one subtype of uterine sarcomas in many retrospective or previous
studies based on the old classiﬁcation, was reviewed extensively,
which has been published in the European Journal of Gynaecologic
Oncology [3].
To introduce the use of targeted therapy for uterine sarcomas,
the conventional therapy for these tumors is summarized in Table 1.
An “en block” surgery is the key and critical procedure for successful
treatment of uterine sarcomas, regardless of their subtypes. In
early-stage uterine sarcomas, total hysterectomy and bilateral
salpingo-oophorectomy (BSO) are the standard treatment of choice.
Some physicians accepted the concept that the indication for
adnexa may be optional, contributing to the uncertainty of the
value of BSO, which can be based on the patient's menopausaly Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
Table 1
Summary of treatment strategies for uterine sarcoma.
Type Main treatmenta Comments
uLMS Surgery Total hysterectomy and
bilateral salpingo-oophorectomy
Early OP Beneﬁts of postoperative
adjuvant therapy not been conﬁrmed
Advanced OP þ CT ± RT Cytoreductive surgery and
trabectedin-based CT (or doxorubicin ±
ifosfamide; gemcitabine ± docetaxel)
LG-ESS Surgery Total hysterectomy and
bilateral salpingo-oophorectomy
Early OP Observation
Advanced OP þ HT Cytoreductive surgery and
hormonal therapy (progestins)
HG-ESS Surgery Total hysterectomy and
bilateral salpingo-oophorectomy
Early OP Total hysterectomy and
bilateral salpingo-oophorectomy
Advanced OP þ CT Cytoreductive surgery and multimodality
treatment (chemotherapy-based therapy)
UUS Surgery Total hysterectomy and bilateral
salpingo-oophorectomy
Early OP þ CT Total hysterectomy and bilateral
salpingo-oophorectomy
Advanced OP þ CT ± RT Cytoreductive surgery and
multimodality treatment
(chemotherapy-based therapy)
CT ¼ chemotherapy; HG-ESS ¼ high-grade endometrial stromal sarcoma;
HT ¼ hormonal therapy; LG-ESS ¼ low-grade endometrial stromal sarcoma;
OP ¼ operation; RT ¼ radiation therapy; uLMS ¼ uterine leiomyosarcoma;
UUS ¼ uterine undifferentiated sarcoma.
a Main treatment: surgery, including total hysterectomy and bilateral salpingo-
oophorectomy, is a key factor in the management of all kinds of uterine sarcomas,
but the lymphadenectomy and the concept of cytoreductive surgery are often
applied in the advanced stage.
M.-S. Yen et al. / Taiwanese Journal of Obstetrics & Gynecology 55 (2016) 625e634626status and disease status. Young women with early-stage uterine
sarcomas, especially tumors limited to the uterus, might be safe
when the decision of ovarian preservation is made [1]. In fact, the
abovementioned concept has been accepted in the management of
younger women with early-stage endometrioid-type endometrial
cancer [4,5]. For UCS, unlike the abovementioned four main sub-
types of uterine sarcomas, the principle of surgery is similar to that
for endometrial cancer [6]. A comprehensive staging surgery,
including total hysterectomy, BSO, pelvic lymph node dissection,
and para-aortic lymph node dissection, is the best of choice for
UCS [3].
The beneﬁts of adjuvant therapy for early-stage uterine sar-
comas are not clear [1,2]. European Organization for Research and
Treatment of Cancer (EORTC) trial 55874 (a randomized study, level
of evidence II) failed to show any beneﬁt of postoperative adjuvant
radiation therapy (50.4 Gy) to treat stage I and II uterine sarcomas
[7]. Similar to the uncertainty of beneﬁts for the use of post-
operative radiation in the management of women with early-stage
uterine sarcomas, a prospective randomized trial also failed to
prove the value of postoperative chemotherapy in women with
early-stage uterine sarcomas [8]. This study enrolled 156 evaluable
patients with stage I or II uterine sarcomas to investigate the effect
of doxorubicin (60 mg/m2 every 3 weeks in 8 courses, n ¼ 75) on
uterine sarcomas compared with observation (n ¼ 81) [8]. There
was no signiﬁcant difference of progression-free survival (PFS) or
overall survival (OS) between the two groups, suggesting an
absence of a beneﬁt for this dose schedule of doxorubicin as
adjuvant treatment for uterine sarcomas [8]. However, this study
showed that a trend emerged in favor of chemotherapy (a recur-
rence rate of 41.3% in the chemotherapy group vs. 53.1% in the
observation group), particularly for patients with uLMS [7]. Ten
years later, another single-arm prospective trial, enrolling 20evaluable patients who underwent total hysterectomy and BSO for
stage I uterine sarcoma, and subsequently received postoperative
adjuvant multiagent chemotherapy with vincristine sulfate, doxo-
rubicin, cyclophosphamide, and dacarbazine, was conducted to
assess the impact on PFS of these patients [9]. In agreement with
Omura et al's report [8], this combination therapy failed to impact
long-term survival signiﬁcantly in this group with stage I uterine
sarcomas [9].
By contrast, for early-stage UCS, postoperative adjuvant therapy
has always been considered because the outcome of these UCS
patients is extremely poor [3]. A population-based analysis based
on the Surveillance, Epidemiology and End Results database eval-
uated 2342 eligible patients with UCS, and the results showed
better overall and cause-speciﬁc survival in the adjuvant radiation
therapy group: 42 versus 22 (p < 0.0001) and 57 versus 28 months
(p < 0.0001), respectively, suggesting the beneﬁts of postoperative
adjuvant radiation therapy for women with UCS [10]. The combi-
nation of chemotherapy and radiation therapy seemed to provide
more survival beneﬁts for patients with UCS. A study showed that
patients with UCS who were treated with a combination of multi-
agent chemotherapy plus radiation therapy had the best chance of
survival [3]. This beneﬁt is not only limited to prolonging disease-
free survival, but also applicable for improving OS [3]. A multi-
institutional study of outcomes in stage IeIII UCS (n ¼ 303)
concluded that observation after surgery was associated with poor
outcomes in UCS compared with either chemotherapy or radiation
therapy alone [11].
For all advanced-stage diseases, regardless of which subtypes of
uterine sarcomas are classiﬁed, the surgical approach should follow
the principle of the management of advanced-stage epithelial
ovarian cancer, tube cancer, primary peritoneal serous carcinoma,
or endometrial cancer [12e17]. All women with advanced-staged
uterine sarcomas should receive a thorough and extensive cytore-
ductive surgery for tumors. Every effort should attempt to mini-
mize the residual tumor initially [1e3]. In addition,
metastasectomy and/or “en bloc removal” should also be performed
if indicated [18,19]. Furthermore, of most importance, post-
operative adjuvant therapy, including multiagent chemotherapy-
based multimodality strategies, should follow primary cytoreduc-
tive surgery. The purpose of these chemotherapy-based multi-
modality treatments is to eradicate all residual tumors in theory.
However, although we manage these advanced-stage and/or
recurrent uterine sarcomas actively and intensively, the prognosis
is still disappointing. Richard Pazdur, a director of the Ofﬁce of
Hematology and Oncology Products in the Unites States Food and
Drug Administration's (US FDA's) Center for Drug Evaluation and
Research, said that the treatment of advanced or metastatic soft-
tissue sarcoma represents a difﬁcult challenge with few effective
therapeutic choices available for patients [20]. Therefore, these
patients and physicians are looking forward to getting new agents
either through conventional antineoplastic agents or through tar-
geted therapy to improve the therapeutic effectiveness. This article
is a series of review articles, and the main topic focuses on targeted
therapy in the management of uterine sarcomas.
Conventional adjuvant therapy
Total hysterectomy plus BSO is a gold-standard therapy for all-
stage uterine sarcomas, and complete cytoreduction, “en bloc
removal,” or metastasectomy of the tumors should be attempted in
advanced or recurrent uterine sarcomas. Postoperative adjuvant
therapy or therapy for inoperable, locally advanced, recurrent, and/
or metastatic uterine sarcomas is suggested for these patients. The
frequently used regimens include single agent of trabectedin,
doxorubicin, and gemcitabine, or the combination regimens of
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bectedin plus other active drugs; however, therapeutic efﬁcacy of
these abovementioned regimens is not fully conﬁrmed. Doxoru-
bicin is shown to have activity against various kinds of soft-tissue
sarcomas and remains a ﬁrst-line standard of care for metastatic
soft-tissue sarcoma, based on the results from a recent randomized
gemcitabineedocetaxel versus doxorubicin in sarcomas trial
comparing a gemcitabineedocetaxel combination with doxoru-
bicin as the ﬁrst-line treatment of metastatic soft-tissue sarcoma,
which showed no signiﬁcant difference of overall response rate or
OS, but dose intensity was lower for the gemcitabineedocetaxel
combination (83%) than for doxorubicin (95%), and a signiﬁcant
number of patients had dose delays (46% for doxorubicin vs. 61% for
the gemcitabineedocetaxel combination) [21]. Combination treat-
ment with dacarbazine or ifosfamide improves responses but not
PFS or OS [22e24]. Doxorubicin, used as a dose-intensity regimen,
plus ifosfamide, taking advantage of the steep doseeresponse
curves for both drugs, results in high response rates, and improved
PFS and possibly OS [25,26]. A recent phase III trial enrolled 455
patients with metastatic soft-tissue sarcoma, and the results
favored the possibility of superiority of dose-intensive doxorubicin
and ifosfamide to doxorubicin alone, because of a lower failure rate
to prevent tumor progression inwomenwhowere treated with the
combination of dose-intensive doxorubicin and ifosfamide
compared with those treated with doxorubicin alone (13% vs. 33%),
contributing to longer median PFS in women who were treated
with the combination therapy than in women treated with doxo-
rubicin alone (7.4 months vs. 4.6 months) [26].
In addition to the abovementioned combination of doxorubicin
and ifosfamide showing potential beneﬁts for PFS in patients with
metastatic soft-tissue sarcomas, trabectedin was reported to act
very well against soft-tissue sarcoma. The US FDA approved tra-
bectedin for the treatment of speciﬁc soft-tissue sarcomas [lip-
osarcoma and leiomyosarcoma (LMS)] that cannot be removed by
surgery, or are advanced or metastatic, based on the relatively
exciting results from a phase III trial (NCT01343277, also coded as
ET743-SAR-3007) [20,27]. The use of trabectedin is approved for
patients who previously received chemotherapy that contained
anthracycline [20]. This trial was conducted to compare trabectedin
(n ¼ 345) with dacarbazine (n ¼ 173) in patients with advanced
liposarcoma or LMS after prior therapy with anthracycline and at
least one additional systemic regimen [27]. The results showed that
trabectedin administration results in a 45% reduction in the risk of
disease progression or death compared with dacarbazine [median
PFS for trabectedin vs. dacarbazine, 4.2 months vs. 1.5 months;
hazard ratio (HR) 0.55, p < 0.001], and the interim analysis of OS
demonstrated a 13% reduction in the risk of death in the trabectedin
group compared with that in the dacarbazine group (median OS for
trabectedin vs. dacarbazine, 12.4 months vs. 12.9 months; HR 0.87,
p ¼ 0.037), suggesting the superiority of trabectedin over conven-
tional dacarbazine treatment in disease control [27].
Another promising agent, eribulin (an analog of anothermarine-
derived compound, halichondrin B), has been tested by a phase III
trial of eribulin versus dacarbazine in liposarcoma and LMS beyond
the ﬁrst-line therapy [28]. Eribulin demonstrated 2-month OS that
was statistically greater than that of placebo, but no difference in
PFS (the converse of the trabectedin trial) [28]. In fact, these ﬁnd-
ings were similar to observations in trials conducted in patients
with metastatic breast and lung cancers [29]. However, the US FDA
has approved trabectedin and eribulin as new therapeutic agents
for certain types of advanced soft- tissue sarcomas, which is indeed
a positive development for patients [20].
Of most importance, trabectedin treatment has two advantages:
(1) the therapeutic beneﬁt of continued disease control can be
maintained by extended trabectedin dosing beyond six cycles,which has been reported in a recent study as well [30]; and (2) the
safety and tolerability of trabectedin were found to be consistent
with extensive prior experience and reports [31]. However, Gepge
D. Demetri (the leader in the ET743-SAR-3007 trial) [27] recognized
the difﬁculty in prolonging OS, despite robust improvement in PFS,
even when the control arm involves a placebo; this struggle might
be similar to the results of a recently reported phase III study [32].
Judson et al [26] concluded that the difference for OS was not
statistically signiﬁcant, although PFS was signiﬁcantly improved.
Based on the unsatisfactory results of the abovementioned
clinical trials, new treatments including targeted therapy should be
considered. To discuss the potentially targeted therapy for uterine
sarcomas, comprehensive descriptions of genomic and molecular
alterations that deﬁne these tumors might be the ﬁrst step in un-
derstanding how the targeted agents work. Investigations to
determine the role of these changes may result in the development
of an advancing pipeline of targeted pharmaceuticals, which help
clinical oncologists interrogate and prosecute individual tumors
[33]. We used the terms, “targeted therapy, leiomyosarcoma” (from
September 1991 toMay 16, 2016) to search the PubMed database for
relevant English-language articles (http://www.ncbi.nlm.nih.gov/
pubmed/?term¼targetedþtherapy%2Cþleiomyosarcoma) and
identiﬁed 74 articles. In addition, we also used the terms “targeted
therapy, uterine sarcoma” (from September 1991 toMay 16, 2016) to
search the PubMed database for relevant English-language articles
(http://www.ncbi.nlm.nih.gov/pubmed/?term¼targetedþtherapy%
2Cþleiomyosarcoma) and identiﬁed 58 articles. Only a few articles
have focused on the clinical use, and the literature on the topic
addressing the targeted therapy for uterine sarcomas is also
extremely limited.
Overview of the potentially targeted therapy for uterine
sarcomas
Many comprehensive reviews addressing the topic of potential
therapeutic targets in sarcomas and/or connective solid tumors
have been published recently [34e38]. These articles displayed a
summary of the potentially targeted therapies for soft-tissue sar-
comas, including uterine sarcomas. The potential targeted site
included the following: (1) genetic aberration, such as mutations of
receptor tyrosine kinase (RTK), aurora kinase A (AURKA), MDM2
proto-oncogene (MDM2), histone deacetylases (HDAC), cyclin-
dependent kinase (CDK) inhibitor 2 a (CDKN2A), CDK inhibitor
(ﬂavopiridol), polyadenosine diphosphate ribose polymerase, suc-
cinate dehydrogenase, and certain types of oncoproteins and/or
loss of tumor suppressor genes (TSGs), for example, phosphatase
and tensin homolog (PTEN), tumor protein p53 (TP53), retinoblas-
toma 1 (RB1), as well as TSG breast cancer 1 (BRCA1) and TSG breast
cancer 2 (BRCA2); (2) aberrant signaling pathway, including
tropomyosin receptor kinase (TRK) signaling, tyrosine kin-
aseetyrosine kinase receptors (TK-RTK) signaling, overexpression
of receptor tyrosine kinase erbB-2/human epidermal growth factor
receptor 2 pathway, epidermal growth factor receptor (EGFR)
pathway, platelet-derived growth factor (PDGF)/platelet-derived
growth factor receptor (PDGFR), insulin-like growth factor 1 and 2
(IGF-1 and IGF-2)/insulin-like growth factor receptor 1/2/A12 (IGF-
1R/IGF-2R/IGFA-12), and brain-derived neurotrophic factor/neuro-
trophic tyrosine kinase receptor type 2; (3) upregulated signal
transduction pathway, such as hyperactivation of the phosphati-
dylinositol 3-kinase/protein kinase B (AKT)/mammalian target of
rapamycin (PI3K/AKT/mTOR) pathway, Wnt/ß-catenin signaling,
tyrosine kinase-like orphan receptor 2, transforming growth factor
ß/bone morphogenetic protein signaling; (4) antiangiogenesis,
such as vascular epidermal growth factor (VEGF)/vascular
epidermal growth factor receptor (VEGFR); (5) immunomodulatory
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receptors, while IFNg activates type II receptors), interleukin (IL)-2,
IL-15, liposomal-muramyl tripeptide phosphatidyl-ethanolamine
(or mifamurtide) that activates monocytes and macrophages,
leading to an increase of a wide variety of immunomodulatory
molecules including tumor necrosis factor-alpha, IL-1, IL-6, IL-8, IL-
12, nitric oxide, prostaglandin E2, lymphocyte function- associated
antigen 1, and intercellular adhesion molecule 1; and (6) mono-
clonal antibodies against tumor antigens, such as disialoganglioside
GD2, tumor necrosis factor-related apoptosis-inducing ligand re-
ceptor (TRAIL-2), or immune checkpoint targets such as cytotoxic T-
lymphocyte-associated protein 4 (ipilimumab) and programmed
cell death protein 1 pathway (PD-1/PD-L1, nivolumab, pem-
brolizumab) [34e38]. In fact, many altered oncogenes, suppressor
genes, signal transduction pathways, surface markers, and sialyla-
tion or glycosylation are also found in various kinds of gynecolog-
ical cancers [39e45]. A summary of some potential targeted
therapies is listed in Table 2.Table 2
Summary of potential therapeutic targets, and clinical or experimental agents for uterin
Targets Targeted method Clinical and/or experi
PDGFePDGFR PDGFR inhibitor Olaratumab (IMC-3G3
imatinib, sunitinib, so
EGFeEGFR EGFR inhibitor Geﬁtinib, erlotinib, ce
VEGFeVEGFR VEGFeVEGFR inhibitor Bevacizumab, aﬂiberc
cediranib, ramucirum
HDAC HDAC inhibitor Vorinostat, valproate
Wnt/b-catenin b-Catenin inhibitor LGK-974, PKF118-310
ER Aromatase inhibitor Letrozole, exemestan
PR Progestins Medroxyprogesteron
HER-2 HER-2 inhibitor Trastuzumab, CP-724
Tyrosine kinases TK inhibitor Cabozantinib
IGFeIGFR IGFeIGFR inhibitor AVE1642, cixutumum
CDK CDK inhibitor Flavopiridol
BDNFeNTRK2 BDNFeNTRK2 inhibitor K252a
PIK3/AKT/mTOR PIK3/AKT/mTOR
pathway inhibitor
Curcumin, everolimu
AURKA AURKA inhibitor MLN8237, MK-5108,
MDM2 MDM2 inhibitor AMG232, RG7112
TSG PARP inhibitor AZD2461, BMN673 (L
(GPI21016/E7016), E7
niraparib (MK4827);
(AG014699/PF036733
c-KIT c-KIT inhibitor Imatinib, pazopanib,
Interferon Immunomodulator IFNa, IFNb, IFNg
Interleukin Immunomodulator IL-1, IL-2, IL-6, IL-8, IL
L-MTP Immunomodulator Liposomal-muramyl t
phosphatidyl-ethanol
TNF Immunomodulator Tumor necrosis factor
LFA-1 Immunomodulator Lymphocyte function
ICAM1 Immunomodulator Intercellular adhesion
Nitric oxide Immunomodulator
Prostaglandin Immunomodulator PG E2 inhibitors
TRAIL-2 Tumor antigen mAb lexatumumab
GD2, GD3, PSA Tumor antigen Dinatuximab (Ch14.1
CTLA-4 Immune checkpoint targets Ipilimumab (cytotoxi
PD-1/PD-L1 Immune checkpoint targets Nivolumab, pembroli
AURKA ¼ aurora kinase A; BDNF ¼ brain-derived neurotrophic factor; CDK ¼ cy
EGF ¼ epidermal growth factor; EGFR ¼ epidermal growth factor receptor; ER ¼ estrog
deacetylases; HER-2 ¼ human epidermal growth factor receptor 2; HGESS ¼ high-grade
IFN ¼ interferon; IGF ¼ insulin-like growth factor; IGFR ¼ insulin-like growth factor
LGESS¼ low-grade uterine endometrial stromal sarcoma; L-MTP¼ liposomal-muramyl tr
double minute 2; NTRK2 ¼ neurotrophic tyrosine kinase receptor type 2; PARP ¼ polyad
PDGF ¼ platelet-derived growth factor; PDGFR ¼ platelet-derived growth factor rece
mTOR ¼ phosphatidylinositol 3-kinase/protein kinase B [AKT]/mammalian target of rap
TNF ¼ tumor necrosis factor; TRAIL-2 ¼ tumor necrosis factor-related apoptosis-inducin
UUS ¼ uterine undifferentiated sarcoma; VEGF ¼ vascular endothelial growth factor; VEClinical trials for uterine sarcomas
Many patients are referred to phase I studies after having failed
multimodality treatment; however, the response rates of these
phase I studies are low, ranging from 5% to 10%. The possible rea-
sons include the advanced nature of the disease of these patients
and the emergence of resistant clones of the tumors, especially
after multimodality treatment. Scientists tried to overcome the
abovementioned limitation, and they obtained a genomic portrait
of the cancers andmatched these cancers, which contained speciﬁc
aberrations, with cognate targeted therapies [39]. In some cases,
higher response rates can be achieved, even for patients with far
advanced cancer and heavily pretreated status. In addition, some
“targeted therapies” provided better PFS compared with prior lines
of conventional, approved unmatched therapy [33]. That is why so
many patients (n ¼ 249) in 24 centers in France received 278
treatment lines with off-label use of targeted therapies for their
sarcoma diseases between October 2008 and October 2011 [46].e sarcomas.
mental agent Diseases
), pazopanib,
rafenib, telatinib
uLMS, LGESS, HGESS
tuximab, vandetanib uLMS, LGESS, HGESS
ept, vandetanib,
ab, telatinib, pazopanib
uLMS, LGESS
uLMS, LGESS
, PNU-74654, K756 uLMS, LGESS
e uLMS, LGESS
e acetate, megestrol acetate uLMS, LGESS
714, CUDC-101 uLMS, HGESS
HGESS, UUS
ab, ﬁgitumumab uLMS
uLMS
uLMS
s, rapamycin, ridaforolimus, temsirolimus uLMS
VE465 uLMS
uLMS
T673), CEP9722, E7449
010, iniparib (BSI201), INO-1001,
olaparib (KU59436/AZD2281), rucaparib
8/CO338); veliparib (ABT888)
uLMS
telatinib HGESS
-12, IL-15
ripeptide
amine or mifamurtide
-associated antigen 1,
molecule 1
8, anti- GD2 mAbs humanized3F8, hu14.18K322A)
c T-lymphocyte-associated protein 4)
zumab (programmed cell death protein 1)
clin-dependent kinase; CTLA-4 ¼ cytotoxic T-lymphocyte-associated protein 4;
en receptor; GD2 ¼ disialoganglioside; GD3 ¼ trisialoganglioside; HDAC ¼ histone
uterine endometrial stromal sarcoma; ICAM1 ¼ intercellular adhesion molecule 1;
receptor; IL ¼ interleukin; LFA-1 ¼ lymphocyte function- associated antigen 1;
ipeptide phosphatidyl-ethanolamine; mAb¼monoclonal antibody; MDM2¼mouse
enosine diphosphate ribose polymerase; PD-1 ¼ programmed cell death protein 1;
ptor; PD-L1 ¼ programmed cell death ligand 1; PG ¼ prostaglandin; PIK3/AKT/
amycin; PR ¼ progesterone receptor; PSA ¼ polysialic acid; TK ¼ tyrosine kinases;
g ligand receptor; TSG ¼ tumor suppressor gene; uLMS ¼ uterine leiomyosarcoma;
GFR ¼ vascular endothelial growth factor receptor.
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were treated with sorafenib, 27% received sunitinib, and 20%
received everolimus [46]. In this retrospective study, the authors
found that off-label targeted therapy can be used for patients with
sarcomas in routine practice, because the toxicity is acceptable and
efﬁcacy is similar to that reported in nonrandomized clinical trials
[46]. To make an extensive review for this topic, we summarized
phase IeIII studies addressing the targeted therapy for sarcoma.
Not all of them were limited to sarcoma within the uterine site.
Phase I trials
In 2014, Cassier et al [47] used data from the European Drug
Development Network database to identify 178 eligible consecutive
phase I trial patients diagnosed with advanced sarcoma or other
mesenchymal tumors, and treated between January 2005 and
December 2007 [38]. Most of the patients (n ¼ 115, 53%) were in
trials of single molecular targeted agents, 49 (22.6%) in trials of
molecular targeted agents combined with chemotherapy, and 43 in
trials of novel cytotoxic agents, either alone (n ¼ 35, 16.1%) or in
combination (n ¼ 8, 3.7%) [47]. Nearly four-ﬁfths of patients were
treated with targeted therapy alone or in combination of chemo-
therapy. These molecular targeted agents included angiogenesis
inhibitors (targeting VEGF, targeting VEGFR, as well as vascular
disrupting agent; n ¼ 43, 19.4%), apoptosis modulators (drugs tar-
geting apoptosis included modulators of p53 function as well as
TRAIL agonists; n ¼ 11, 5.1%), cell cycle modulators (cell cycle in-
hibitors included inhibitors of surviving, of Polo-like kinase, and of
AURKA; n ¼ 11, 5.1%), HDAC inhibitors (n ¼ 10, 4.6%), IGF-1R
antagonist (n ¼ 17, 7.8%), and others, including inhibitors of KIT
and PDGFR not active against VEGFRs, inhibitors of PKC (protein
kinase C), inhibitors of aminopepetidases, and inhibitors of EGFR,
FGFR (ﬁbroblast growth factor receptor), mitogenactivated protein
kinase kinases 1 and 2 (MEK), and MET [47].
A phase I study of olaratumab (IMC-3G3), a fully human
monoclonal antibody that selectively binds human PDGFRa and
blocks ligand binding, in patients with advanced sarcomas showed
preliminary antitumor activity, had an acceptable safety proﬁle,
andwas well tolerated [48,49]. Another agent, ramucirumab, a fully
human immunoglobulin G1 monoclonal antibody receptor antag-
onist designed to block the ligand-binding site of VEGFR-2, in a
phase I trial, was found to be well tolerated, and prolonged stable
disease was observed in a phase II trial [50].
Some targeted agents aremultifunctional. For example, telatinib
(BAY 57-9352), an orally available tyrosine kinase inhibitor (TKI) of
VEGFR-2, VEGFR-3, PDGFR-b, and c-Kit, in a phase I trial, was found
to be safe and up to 50.9% of patients could achieve the stable
condition [51].
The rationale of the combination of targeted therapy and
chemotherapy is based on the observation that targeted therapy
might potentiate chemotherapy efﬁcacy. For example, Luke et al
[52] used the combination of a CDK inhibitor (ﬂavopiridol) and
doxorubicin in the management of advanced sarcomas, and found
that the CDK inhibitor can potentiate doxorubicin efﬁcacy.
Furthermore, a phase Ib to II trial in which 133 patients were ran-
domized to receive doxorubicin with or without olaratumab met
the primary end point of improved PFS, with a median PFS of
6.6 months in the combination arm versus 4.1 months in the
doxorubicin arm (HR 0.67) [53]. In addition, the combination of
olaratumab and doxorubicin also yielded a statistically signiﬁcant
improvement in median OS compared with doxorubicin alone
(25 months vs. 10.7 months) [53].
However, based on the summary of all phase I trials, the results
were relatively disappointing, because the overall response rate
was 2.2%, and 3-month and 6-month nonprogression rates were31.5% and 11.0%, respectively [47]. All reﬂected the limited activity
of these targeted agents in sarcomas, although response by itself is
only of limited value in the assessment of newer agents for sar-
comas, and the most adequate surrogate end point for efﬁcacy in
this population is still unknown [47]. For all clinical trials
addressing cancer treatment, end points need to reﬂect beneﬁts to
patients and show that changes in tumor size, either in absolute
terms (response and/or progression) or relative to control (pro-
gression), are clinically relevant [54e57].
Complete response rate is very limited in the phase I trial of
targeted therapy, but there is no doubt that nearly half of the pa-
tients had stable diseases after the targeted therapy [47]. This
limited activity of targeted therapy is nevertheless comparable
with that observed in patients with carcinoma entering phase I
trials and similar to that of older cytotoxic drugs available for the
treatment of patients with advanced sarcomas [58], suggesting that
some patients with sarcomas derive beneﬁt from targeted therapy
in this setting, especially pre-heavily treated patients without any
remaining standard therapeutic option.
Phase II trials
Olaratumab, as shown above, combined with doxorubicin yiel-
ded a statistically signiﬁcant improvement in median OS compared
with doxorubicin alone in phase Ib and II trials [53], resulting in an
initiation of a phase III trial [38]. Sorafenib, a small molecular in-
hibitor of TK, VEGFR 2/3, PDGFRb, and RAF (C-Raf moreover) ki-
nases, has recently been used to treat 12 uLMS patients, resulting in
stable disease of four patients in a phase II study [59]. Sorafenib
activity has been explored in several phase II studies, showing better
results in sarcoma with vascular differentiation and/or angio-
sarcoma rather than in LMS [60]. Sunitinib, one multitargeted TKI,
was studied in a phase II trial enrolling patients with pretreatment
of one to two prior lines of chemotherapy [61]. All (n ¼ 23) were
treated with sunitinib 50 mg by mouth daily for 4 weeks, followed
by a 2-week break, and only two patients (8.7%) achieved a partial
response and four patients [17.4%; 90% conﬁdence interval (CI),
6.2e35.5%] were progression free at 6 months [61]. Median PFS and
OS were 1.5 months and 15.1 months, respectively [61]. Taken
together, neither sunitinib malate nor sorafenib achieved good
objective responses in soft-tissue sarcoma and uLMS trials [62].
Imatinib mesylate, a competitive inhibitor of tyrosine kinases
selectively associated with c-Kit and PDGF receptors (especially
PDGFb receptor), was used to treat 28 patients with LMS, and six
patients had stable disease in another phase II study [63]. As a
matter of fact, translocation between chromosome 17 and 22 results
in the COLIA1-PDGFb fusion gene, leading to overexpression of a
growth factor that acts as a PDGFRb ligand andpromotes continuous
activation of PDGFRb by an autocrine and paracrine loop [60]. Evi-
dence that imatinib showed a 50% overall response rate leads to the
registration of this agent for the management of certain-type soft-
tissue sarcomas (dermatoﬁbrosarcoma protuberans) [60].
Pazopanib, a multitargeted TKI, is an oral angiogenesis inhibitor
that targets VEGF receptors (VEGFR 1/2), PDGF receptors (PDGFRa
andPDGFRb), and c-kit receptors [64]. Pazopanib acts to prevent ATP
binding on the intracellular domain of the TK receptor, consequently
blocking the signaling pathway [60]. In a phase II trial enrolling 142
patients, pazopanib was administered at a dose of 800 mg/d, and
showed 44% and 39% of the PFS rates (primary end point of PFS at
12weeks) in the LMS and other sarcoma subtypes, respectively [64].
Several phase II trials are exploring the role of pazopanib in the
management of various kinds of sarcomas using pazopanib either
alone or in combination with conventional chemotherapy [60].
The activity of bevacizumab, a humanized recombinant anti-
body that blocks the binding of VEGF to VEGFR, inhibiting
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patients with metastatic soft-tissue sarcomas [65]. Among 17 pa-
tients treated with bevacizumab and doxorubicin, two had an
objective response, similar to doxorubicin alone; however, 65% of
the patients maintained prolonged stable disease, reporting
considerable side effects (cardiotoxicity) [65].
Everolimus, an oral analog of sirolimus (mTOR inhibitors), was
administered in 38 patients with recurrent or metastatic soft-tissue
sarcoma in a phase II study, showing 27% of the whole group of
patients and 67% of patients with angiosarcoma at the primary end
point of 16weeks PFS [58]. Median PFS and OSwere 1.9months and
5.8 months, respectively [66]. Ridaforolimus (AP23573), a non-
prodrug rapamycin analog of mTOR inhibitor with better pharma-
ceutical and pharmacological characteristics than sirolimus, was
tested in a phase II study enrolling 215 patients with advanced
sarcomas [67]. Intravenous ridaforolimus (15 mg) was adminis-
tered ﬁve times a day every other week, showing 1.9% of patients
with objective response and 28.8% of patients with clinical beneﬁts
[67]. Median OS was 40 weeks [67].
A phase II study was conducted to compare PFS of patients with
IGF-1R-positive soft-tissue sarcoma (group A), IGF-1R-positive
bone sarcomas (group B), or IGF-1R-negative bone and soft-tissue
sarcoma (group C) treated with weekly cixutumumab (6 mg/kg,
intravenous) and temsirolimus (25 mg, intravenous ﬂat dose) in 6-
week cycles [68]. The results showed that of 54 patients, seven
(31%) in the IGF-1R-positive soft-tissue sarcoma group, 19 (35%) in
the IGF-1R-positive bone sarcoma group, and 21 (39%) in the IGF-
1R-negative group were progression free at 12 weeks, suggesting
that the combination of cixutumumab and temsirolimus shows
clinical activity in patients with sarcoma, regardless of whether
there is IFGF-1R expression or not [68]. A phase II study evaluated
the primary end point of PFS of 71 patients with advanced soft-
tissue sarcomas who received 2 prior chemotherapeutics, who
were treated with a combination of selumetinib (MEK inhibitor,
oral 50 mg twice per day) and temsirolimus (20 mg intravenously
weekly) or selumetinib (oral 75mg twice per day) [69]. The PFS rate
at 4 months was 50% (95% CI, 0.19e0.81) in the combination ther-
apy group compared with 0% in the selumetinib group in the LMS
cohort, suggesting that while single-agent selumetinib did not have
signiﬁcant activity in soft-tissue sarcoma, the combination of
selumetinib and temsirolimus seemed to be active for LMS [69].
Panobinostat (40 mg 3 times a week), an HDAC inhibitor,
modifying the acetylation status of histone and nonhistone pro-
teins preventing heat-shock protein-90 activation and the conse-
quent gene transcription leading the tumoral cells to apoptosis
without showing major toxicities on normal cells, has been tested
in a phase II study (n ¼ 47, including LMS, 21%), which showed that
no partial responses were achieved, although six patients had
stable disease [70]. However, results from this trial were not
encouraging, reporting a high rate of severe adverse events [60].
Another phase II study of SB939, a novel oral pan-HDAC inhibitor, in
patients with translocation-associated recurrent/metastatic sar-
comas showed stabilization in eight out of 14 response-assessable
patients and 49% of PFS rate at 3 months [71]. In addition, SB939
has favorable pharmacological properties and manageable side
effects in this phase II trial [71].
CD4 inhibitor (PD0332991, palbociclib) has been evaluated in a
phase II trial enrolling 29 patients, and results showed one partial
response and 66% of patients with PFS at 12weeks [72]. Median PFS
was 18 weeks [72]. A good correlation between CDK4 over-
expression and efﬁcacy of PD0332991 was noted in various sar-
coma subtypes, suggesting the value to enter a phase III trial,
especially for patients with liposarcoma [37,60].
Alisertib, an oral small-molecule inhibitor of AURKA, was tested
in a phase II trial enrolling 72 patients with soft-tissue sarcoma[73]. Results showed that the PFS rate at 3 months was 73%, 57%,
44%, and 39% for liposarcomas, Malignant Peripheral Nerve Sheath
Tumor (MPNST), LMS, and undifferentiated pleomorphic sarcoma,
respectively, although the PFS rate at 3 months was only 23% in
other subtypes of sarcomas [73].
Selinexor, a selective inhibitor of nuclear export, acts by binding
covalently to human XPO1, which is a member of the karyopherin b
superfamily of nuclear transport proteins, facilitating the nuclear
export of RNA and proteins (such as p53, retinoblastoma, and
adenomatous polyposis coli) and cell cycle regulators (such as p21),
and playing a role in mitotic progression and chromosome segre-
gation [38]. Recent preclinical data have shown that selinexor was
able to induce apoptosis in liposarcoma and other sarcoma sub-
types both in vitro and in vivo [74], resulting in an ongoing phase II/
III clinical trial that will test its efﬁcacy in advanced liposarcoma
(NCT02606461).
Crizotinib, an oral small-molecule TKI targeting ALK, MET, and
ROS1 tyrosine kinases, has been evaluated in an ongoing EORTC
phase II trialdCross-tumoral Phase 2With Crizotinib (CREATE) trial
(NCT01524926)dwhich is exploring crizotinib in patients with
advanced tumors including soft-tissue sarcoma with ALK/MET
rearrangements (Inﬂammatory Myoﬁbroblastic Tumor (IMT),
alveolar soft part sarcoma, and clear cell sarcoma), [38].
Phase III trials
A randomized phase III trial was conducted to determine
whether the addition of bevacizumab (VEGFeVEGFR inhibitor) to
gemcitabineedocetaxel increases PFS in uLMS [75]; however, the
results showed that median PFS was 6.2 months for gemcitabi-
needocetaxel plus placebo versus 4.2 months for gemcitabi-
needocetaxel plus bevacizumab (HR 1.12; p ¼ 0.58); in addition,
median OS was 26.9 months for gemcitabineedocetaxel plus pla-
cebo and 23.3 months for gemcitabineedocetaxel plus bev-
acizumab (HR 1.07; p ¼ 0.81), suggesting little or no beneﬁt of the
additional antiangiogenesis agents on the conventional combina-
tion chemotherapy in the management of uterine sarcomas [75].
By contrast, the value of targeted therapy for uterine sarcomas
has been investigated in a recent large retrospective study, which
was based on two EORTC Soft Tissue and Bone Sarcoma Group
phase III clinical trials 62043 and 62072 [32,34,76]. Pazopanib
(PDGFR inhibitor) showed longer median PFS compared with pla-
cebo [4.6 months; 95% CI 3.7e4.8 months in the pazopanib group
vs.1.6months (0.9e1.8months) in the placebo group]with an HR of
0.31 (95% CI 0.24e0.40; p < 0$0001); OS seemed not to reach a
statistically signiﬁcant difference between the two groups
[12.5 months; 95% CI 10.6e14.8 months in the pazopanib group vs.
10.7 months (8.7e12.8) months in the placebo group], with an HR
of 0.86 (95% CI 0.67e1.11; p ¼ 0.25) in the pazopanib group for the
metastatic soft-tissue sarcoma (PALETTE) trial [32]. Subgroup
analysis, including 44 patients with uterine sarcoma treated with
pazopanib (39 patients with uLMS) showed that ﬁve patients (11%),
all with uLMS, had a partial response (95% CI 3.8e24.6), andmedian
PFS was 3 months (95% CI 2.5e4.7 months) with median OS of
17.5 months (95% CI 11.1e19.6 months), suggesting that pazopanib
shows signs of activity in patients with uterine sarcoma, despite
heavy pretreatment [32,76].
Ridaforolimus (AP23573) was tested in a phase III trial in pa-
tients with advanced sarcomasdthe Sarcoma Multi-Center Clinical
Evaluation of Efﬁcacy of Ridaforolimus study (n ¼ 702) [77]. The
purpose of the study was to evaluate whether oral ridaforolimus
could prevent and control tumor growth for a prolonged period of
time in patients with metastatic soft-tissue sarcoma responding to
chemotherapy [77]. The results showed that ridaforolimus-treated
patients showed a 28% reduction in the risk of developing
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ridaforolimus and 14.7 weeks for placebo) compared with the
placebo group. However, only a slight beneﬁt of OS was reported
(90.6 weeks vs. 85.3 weeks in the ridaforolimus and placebo
groups, respectively) [77]; as a result, the US FDA did not grant
approval for ridaforolimus as maintenance therapy after chemo-
therapy in patients with advanced or metastatic sarcomas [34].
Ombrabulin (AVE8062), a prodrug and a combretastatin deriv-
ative, which is one of the tumor vascular-disrupting agents and
tubulin depolymerizing drugs, selectively disrupts the tumor
endothelial cytoskeleton and causes rapid tumor vascular shut-
down and necrosis; therefore, ombrabulin targets established tu-
mor vasculature and might be more effective against large tumor
masses [78]. Based on synergistic antitumor and complementary
spatial activity of the combination of tumor vascular-disrupting
agents and cytotoxic chemotherapy to tumor, Blay and colleagues
[79] presented the results of a phase III trial that assessed the safety
and efﬁcacy of ombrabulin plus cisplatin versus placebo plus
cisplatin in 355 patients with advanced sarcoma who had previ-
ously received anthracyclines and ifosfamide. The results showed
that the absolute improvement in PFS with ombrabulin plus
cisplatin compared with cisplatin alone was slight (median
1.54 months vs. 1.41 months; HR 0.76); however, it did not show a
clinically meaningful beneﬁt in patients with advanced sarcomas to
support its use as a therapeutic option, although in the prespeciﬁed
subtypes, such as LMS, liposarcoma, and other types, improvement
in PFS was signiﬁcant [79].
Future perspectives
Although select chemotherapy agents have activity against
sarcoma, their overall effect against sarcoma remains minimal. The
modern concept of pathology- or histology-driven chemotherapy
and the new developments on molecular targeted agents may
signiﬁcantly change the medical approach toward sarcoma. Now, a
variety of agents are under evaluation for the management of sar-
comas. The biological rationale for these agents is as broad as the
variety of biological pictures, including differential microRNA sig-
natures [80] that encompass sarcoma and will need phase II and III
trials to deﬁne their role (both safety and efﬁcacy) as sarcoma
therapeutics [38]. A multitargeted TKI, mTOR inhibitors, various
kinds of growth factor and/or growth factor receptor inhibitors, and
antiangiogenic agents, including vascular disrupting agents, might
represent promising drugs for the treatment of sarcoma, although
there is still a big gap between basic research (bench) and clinical
use (bed). Immune checkpoint inhibitors and/or immunotherapy,
although promising, have not shown any result in the ﬁeld of sar-
coma management yet. Two phase II trials are going to test their
role in themanagement of sarcoma, including (1) SARC028, a phase
II study of the anti-PD1 antibody pembrolizumab (MK-3475) in
patients with advanced sarcomas (ClinicalTrials.gov identiﬁer:
NCT02301039), and (2) nivolumab with or without ipilimumab in
treating patients with metastatic or unresectable sarcoma
(ClinicalTrials.gov identiﬁer: NCT02500797). We are looking for-
ward to seeing their results.
One of cancer gremlin antigens, NY-ESO-1, a valid target for
engineered T cells, has also been tested in certain types of sarcomas
[38]. Metabolic changes and translocation fusion sequences are also
the potentially targeted sites for sarcoma treatment.
Conclusion
The choice of the most appropriate treatment in uterine sar-
comas is challenging. Anthracycline and/or ifosfamide are usually
considered as the ﬁrst-line systemic therapy for sarcomas;however, the second-line therapy has not been standardized yet;
high-dose continuous ifosfamide is frequently used in adult-type
soft-tissue sarcomas, and gemcitabine and docetaxel in LMS [60].
In fact, a big gap of more than 10 years in which no new drugs for
patients with advanced and metastatic sarcomas were approved in
the USA has been passed by a recent series of successful random-
ized trials [38]. The agents with most recent approval include
pazopanib as a targeted therapy, and two chemotherapy agents
such as trabectedin and eribulin [38]. Signiﬁcant advances in mo-
lecular biology and genetic research have allowed better identiﬁ-
cation of molecular signatures of sarcoma, and biomarker
identiﬁcation and validated screening are needed to provide the
optimal treatment strategy.
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